Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 38 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL August 25, 2020 ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March February 24, 2025 Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to... June 16, 2021 Load more HOT NEWS For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects Beloved Preschool Teacher Dies of Breast Cancer, Leaving Behind 9-Year-Old Son What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials Neoadjuvant Camrelizumab Plus Chemotherapy Demonstrate Superior pCR Compared to Chemotherapy Alone...
